Biosplice Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Biosplice Therapeutics is a biotechnology research company based in San Diego, California, with 11 to 50 employees. The company is developing lorecivivint (LOR) for knee osteoarthritis, a small-molecule suspension intended for intra-articular injection into the knee joint. LOR's mechanism involves selective inhibition of DYRK1A and CLK2 kinases, with potential anti-inflammatory and cartilage-protective effects described in its program. Its development program has explored once-per-year or every-six-month dosing and has reported improvements in pain, function, and medial joint space width, alongside a favorable safety profile, although LOR has not yet received FDA approval. Through its affiliate TenaRx, Biosplice is pursuing additional therapies in diabetes, oncology, and neurology, and recent activities include a preclinical collaboration with Novo Nordisk and a Department of Defense–funded neurology project with The Roskamp Institute.

Sign up for free to view info

Company overview Employee directory